<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6963304/results/search/disease/results.xml">
  <result pre="member of the Herpesviridae, is the causative agent of an" exact="acute" post="infectious disease in a variety of animals. The emergence"/>
  <result pre="of the Herpesviridae, is the causative agent of an acute" exact="infectious disease" post="in a variety of animals. The emergence of a"/>
  <result pre="the Herpesviridae, is the causative agent of an acute infectious" exact="disease" post="in a variety of animals. The emergence of a"/>
  <result pre="antiviral activity against PRV in the early phase of the" exact="viral" post="replication cycle. Moreover, we found that germacrone does not"/>
  <result pre="PRV germacrone antiviral 1. Introduction Pseudorabies (PR), an acute, febrile" exact="infectious disease" post="caused by pseudorabies virus (PRV), usually occurs in sows"/>
  <result pre="germacrone antiviral 1. Introduction Pseudorabies (PR), an acute, febrile infectious" exact="disease" post="caused by pseudorabies virus (PRV), usually occurs in sows"/>
  <result pre="can persist in the host for a long time after" exact="infection" post="makes its prevention and control challenging [13]. The development"/>
  <result pre="drugs has become imperative since PRV vaccines do not provide" exact="complete" post="protection. Due to the large specific surface area and"/>
  <result pre="Porcine parvovirus (PPV), Feline calicivirus (FCV), and Porcine reproductive and" exact="respiratory" post="syndrome virus (PRRSV) replication [16,20,21,22]. Germacrone has inhibitory effects"/>
  <result pre="parvovirus (PPV), Feline calicivirus (FCV), and Porcine reproductive and respiratory" exact="syndrome" post="virus (PRRSV) replication [16,20,21,22]. Germacrone has inhibitory effects on"/>
  <result pre="and Influenza B viruses in the early stages of the" exact="viral" post="cycle and can protect mice from fatal infection [20]."/>
  <result pre="of the viral cycle and can protect mice from fatal" exact="infection" post="[20]. However, it does not block PRRSV adsorption and"/>
  <result pre="was to explore the antiviral effects of germacrone on PRV" exact="infection" post="and its antiviral mechanism. We found that germacrone can"/>
  <result pre="replication in a dose-dependent manner at the early stage of" exact="viral" post="replication. 2. Materials and Methods 2.1. Cells and Virus"/>
  <result pre="and cultured at 37 °C in a CO2 humidified incubator." exact="Variant" post="PRV and PRV vaccine strain Barth K61 were propagated"/>
  <result pre="Vero cells cultured in DMEM supplemented with 2% FBS. The" exact="viral" post="titers were titrated in Vero cells. 2.2. Chemicals, Antibodies"/>
  <result pre="M and 10 mg/mL concentration, respectively, and filter-sterilized. The following" exact="primary" post="antibodies were purchased from commercial resources: rabbit anti-β-Actin pAb"/>
  <result pre="(China); mouse anti-PRV-gB mAb (LD-DW-Z0022-2) from lv du (China). The" exact="secondary" post="antibodies used in western blotting, including DyLight 800 goat"/>
  <result pre="anti-rabbit IgG (H+L) (074-1506), were purchased from KPL (Gaithersburg, MD)." exact="Secondary" post="antibody used in confocal microscopy, including goat anti-mouse–FITC (Fluorescein"/>
  <result pre="an automatic microplate reader (TECAN Infinite® 200 PRO). 2.4. Virus" exact="Infection" post="and Viral Titer Assay Variant PRV and PRV vaccine"/>
  <result pre="microplate reader (TECAN Infinite® 200 PRO). 2.4. Virus Infection and" exact="Viral" post="Titer Assay Variant PRV and PRV vaccine strain Barth"/>
  <result pre="Infinite® 200 PRO). 2.4. Virus Infection and Viral Titer Assay" exact="Variant" post="PRV and PRV vaccine strain Barth K61 were propagated"/>
  <result pre="DNA Kit (TIAN GEN DP304) was used for DNA extraction." exact="Total" post="RNA from Vero or LLC-PK1 cells was extracted using"/>
  <result pre="s. Specific primers are shown in Table 1. The PRV" exact="viral" post="gB gene level was determined by absolute quantification real-time"/>
  <result pre="for 30 min. The fixed cells were then incubated with" exact="primary" post="antibodies (mouse anti-PRV-gB mAb, 1:1000) for 2 h, washed"/>
  <result pre="2 h, washed five times with PBS, and incubated with" exact="secondary" post="antibodies (goat anti-mouse–ITC) for 1 h at 37 °C"/>
  <result pre="(4′,6-diamidino-2-phenylindole) for 15 min to stain the nuclei. Images were" exact="acquired" post="by using a fluorescence microscope (Nikon) with a video"/>
  <result pre="for 1 h at room temperature and incubated with specified" exact="primary" post="antibodies overnight. After being washed with PBST for five"/>
  <result pre="with PBST for five times, the membrane was incubated with" exact="secondary" post="antibodies (DyLight 800 goat anti-mouse IgG or DyLight 800"/>
  <result pre="after treatment with 150 μM germacrone. No changes in cell" exact="morphology" post="were detected at 150 μM germacrone (Figure 1D). To"/>
  <result pre="with 150 μM germacrone for 24 h. Germacrone significantly inhibited" exact="viral" post="replication compared with control cells and DMSO treatment (Figure"/>
  <result pre="germacrone for 2 h at room temperature and determined the" exact="infectious" post="titer by TCID50 on Vero cells. Germacrone did not"/>
  <result pre="with 10–150 μM of germacrone inhibited PRV-gB protein levels and" exact="viral" post="proliferation in Vero cells (Figure 3A,B). On the other"/>
  <result pre="treatment with 50–150 μM germacrone inhibited PRV-gB protein levels and" exact="viral" post="proliferation in PK-1 cells (Figure 3C,D). In addition, a"/>
  <result pre="reflect the concentration of germacrone that is required to abolish" exact="infectious" post="virus particle production by 50%. Figure 3G shows the"/>
  <result pre="50%. Figure 3G shows the EC50 values for germacrone following" exact="infection" post="with PRV in Vero or PK-1 cells. The EC50"/>
  <result pre="cells and incubated for 1 h at 4 °C. The" exact="viral" post="genome load was then quantified by Q-PCR via amplification"/>
  <result pre="control-treated cells (Figure 5A,B), suggesting that germacrone does not affect" exact="viral" post="attachment to cells. Next, cells were inoculated with PRV"/>
  <result pre="2.5) to remove bound virus [25]. After 6 hpi, the" exact="viral" post="genome load was quantified by Q-PCR via amplification of"/>
  <result pre="It has been reported that DG and LiCl inhibit PRV" exact="infection" post="of Vero cells [15]. Compared with LiCl, DG did"/>
  <result pre="cells [15]. Compared with LiCl, DG did not inhibit PRV" exact="infection" post="after virus adsorption, and it seemed that this drug"/>
  <result pre="[2,30]. The Bartha-K61 vaccine is inadequate to protect pigs from" exact="infection" post="with variant PRV [8], and thus antiviral therapeutics may"/>
  <result pre="to animals and possibly humans. A case of suspected PRV" exact="infection" post="in humans occurred in China in 2017. The patient"/>
  <result pre="China in 2017. The patient presented with fever, headaches, and" exact="visual" post="impairment [4]. Many countries have also reported PRV interspecies"/>
  <result pre="or cellular factors, some of which may be required for" exact="viral" post="replication. Therefore, we speculate that germacrone may inhibit PRV"/>
  <result pre="PRV. We show it acts at the early stage of" exact="infection" post="and could serve as a potential treatment. However, the"/>
  <result pre="of China (2016YFD0500402) and the Fundamental Research Funds for the" exact="Central" post="Universities Y0201900459, the Natural Science Foundation of Jiangsu Province"/>
  <result pre="IAV Porcine parvovirus PPV Feline calicivirus FCV Porcine reproductive and" exact="respiratory" post="syndrome virus PRRSV 50% effective concentration EC50 50% cytotoxic"/>
  <result pre="Porcine parvovirus PPV Feline calicivirus FCV Porcine reproductive and respiratory" exact="syndrome" post="virus PRRSV 50% effective concentration EC50 50% cytotoxic concentration"/>
  <result pre="effective concentration EC50 50% cytotoxic concentration CC50 50% tissue culture" exact="infectious" post="dose TCID50 Indirect immunofluorescence assay IFA Multiplicity of infection"/>
  <result pre="culture infectious dose TCID50 Indirect immunofluorescence assay IFA Multiplicity of" exact="infection" post="MOI References References 1.LiX.ZhangW.LiuY.XieJ.HuC.WangX.Role of p53 in pseudorabies virus"/>
  <result pre="Impact on neurovirology and veterinary medicineMicrobiol. Mol. Biol. Rev.20056946250010.1128/MMBR.69.3.462-500.200516148307 3.MarcacciniA.LópezP.M.QuirogaM.I.BermúdezR.NietoJ.M.AlemañN.Pseudorabies" exact="virus infection" post="in mink: A host-specific pathogenesisVet. Immunol. Immunopathol.200812426427310.1016/j.vetimm.2008.03.01318490062 4.AiJ.W.WengS.S.ChengQ.CuiP.LiY.J.WuH.L.ZhuY.M.XuB.ZhangW.H.Human Endophthalmitis"/>
  <result pre="on neurovirology and veterinary medicineMicrobiol. Mol. Biol. Rev.20056946250010.1128/MMBR.69.3.462-500.200516148307 3.MarcacciniA.LópezP.M.QuirogaM.I.BermúdezR.NietoJ.M.AlemañN.Pseudorabies virus" exact="infection" post="in mink: A host-specific pathogenesisVet. Immunol. Immunopathol.200812426427310.1016/j.vetimm.2008.03.01318490062 4.AiJ.W.WengS.S.ChengQ.CuiP.LiY.J.WuH.L.ZhuY.M.XuB.ZhangW.H.Human Endophthalmitis"/>
  <result pre="sequence of the pseudorabies virus genomeJ. Virol.20047842444010.1128/JVI.78.1.424-440.200414671123 6.YuT.ChenF.KuX.FanJ.ZhuY.MaH.LiS.WuB.HeQ.Growth characteristics and" exact="complete" post="genomic sequence analysis of a novel pseudorabies virus in"/>
  <result pre="Dynamics of Pseudorabies VirusJ. Infect. Dis.20192191705171510.1093/infdis/jiy73130590733 11.WuR.BaiC.SunJ.ChangS.ZhangX.Emergence of virulent pseudorabies" exact="virus infection" post="in Northern ChinaJ. Vet. Sci.20131436336523820207 12.GuZ.Q.HouC.C.SunH.F.YangW.P.DongJ.BaiJ.JiangP.Emergence of highly virulent"/>
  <result pre="of Pseudorabies VirusJ. Infect. Dis.20192191705171510.1093/infdis/jiy73130590733 11.WuR.BaiC.SunJ.ChangS.ZhangX.Emergence of virulent pseudorabies virus" exact="infection" post="in Northern ChinaJ. Vet. Sci.20131436336523820207 12.GuZ.Q.HouC.C.SunH.F.YangW.P.DongJ.BaiJ.JiangP.Emergence of highly virulent"/>
  <result pre="15.SuiX.YinJ.RenX.Antiviral effect of diammonium glycyrrhizinate and lithium chloride on cell" exact="infection" post="by pseudorabies herpesvirusAntivir. Res.20108534635310.1016/j.antiviral.2009.10.01419879899 16.FengJ.BaiX.CuiT.ZhouH.ChenY.XieJ.ShiQ.WangH.ZhangG.In Vitro Antiviral Activity of"/>
  <result pre="16.FengJ.BaiX.CuiT.ZhouH.ChenY.XieJ.ShiQ.WangH.ZhangG.In Vitro Antiviral Activity of Germacrone Against Porcine Reproductive and" exact="Respiratory" post="Syndrome VirusCurr. Microbiol.2016731710.1007/s00284-016-1042-826960292 17.Raduloviä‡N.S.Dekiä‡M.S.Stojanoviä‡-Radiä‡Z.Z.Zoraniä‡S.K.Geranium macrorrhizum L. (Geraniaceae) essential oil:"/>
  <result pre="Vitro Antiviral Activity of Germacrone Against Porcine Reproductive and Respiratory" exact="Syndrome" post="VirusCurr. Microbiol.2016731710.1007/s00284-016-1042-826960292 17.Raduloviä‡N.S.Dekiä‡M.S.Stojanoviä‡-Radiä‡Z.Z.Zoraniä‡S.K.Geranium macrorrhizum L. (Geraniaceae) essential oil: A"/>
  <result pre="subtilisChem. Biodivers.201072783280021072778 18.LimM.S.ChoungS.Y.JeongK.W.Germacrone Inhibits Estrogen Receptor α-Mediated Transcription in MCF-7" exact="Breast" post="Cancer CellsPhytother. Res.2016302036204327573551 19.LiuY.WangW.FangB.MaF.ZhengQ.Anti-tumor effect of germacrone on human"/>
  <result pre="Biodivers.201072783280021072778 18.LimM.S.ChoungS.Y.JeongK.W.Germacrone Inhibits Estrogen Receptor α-Mediated Transcription in MCF-7 Breast" exact="Cancer" post="CellsPhytother. Res.2016302036204327573551 19.LiuY.WangW.FangB.MaF.ZhengQ.Anti-tumor effect of germacrone on human hepatoma"/>
  <result pre="within specific geographic regionsVirology2017506929810.1016/j.virol.2017.03.01328363130 24.PanJ.MiaoD.ChenL.Germacrone reverses adriamycin resistance in human" exact="chronic" post="myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expressionChem."/>
  <result pre="geographic regionsVirology2017506929810.1016/j.virol.2017.03.01328363130 24.PanJ.MiaoD.ChenL.Germacrone reverses adriamycin resistance in human chronic myelogenous" exact="leukemia" post="K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expressionChem. Biol. Interact.2018288323710.1016/j.cbi.2018.04.01229655913"/>
  <result pre="Curcuma wenyujinHelv. Chim. Acta2010921665167210.1002/hlca.200900059 32.AnJ.F.SunY.ZhangQ.L.ZhangF.L.ZhangJ.L.The effects of germacrone on lipopolysaccharide-induced" exact="acute" post="lung injury in neonatal ratsCell. Mol. Biol.20146081225399081 33.LiuB.GaoY.Q.WangX.M.WangY.C.FuL.Q.Germacrone inhibits"/>
  <result pre="32.AnJ.F.SunY.ZhangQ.L.ZhangF.L.ZhangJ.L.The effects of germacrone on lipopolysaccharide-induced acute lung injury in" exact="neonatal" post="ratsCell. Mol. Biol.20146081225399081 33.LiuB.GaoY.Q.WangX.M.WangY.C.FuL.Q.Germacrone inhibits the proliferation of glioma"/>
  <result pre="in neonatal ratsCell. Mol. Biol.20146081225399081 33.LiuB.GaoY.Q.WangX.M.WangY.C.FuL.Q.Germacrone inhibits the proliferation of" exact="glioma" post="cells by promoting apoptosis and inducing cell cycle arrestMol."/>
  <result pre="is regarded as a nontoxic concentration of drugs. (D) Cell" exact="morphology" post="of Vero and PK-1 cells in the negative control"/>
  <result pre="three independent experiments. Figure 2 Germacrone reduces the production of" exact="infectious" post="PRV particles and is not viricidal. (A,B) Vero (A)"/>
  <result pre="DMSO at room temperature for 1 h. After incubation, the" exact="infectious" post="titer was determined by TCID50 in Vero cells. Data"/>
  <result pre="the unbound virus particles were washed with serum-free DMEM, the" exact="viral" post="genome load was quantified by Q-PCR by amplification of"/>
  <result pre="After washing three times with PBS (pH = 2.5), the" exact="viral" post="genome load was quantified by Q-PCR by amplification of"/>
 </snippets>
</snippetsTree>
